Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Operating Leases (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Operating Leases for 3 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 19.82% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2025, down 19.82% year-over-year, with the annual reading at $6.5 million for FY2025, 19.82% down from the prior year.
  • Operating Leases for Q4 2025 was $6.5 million at Inhibrx Biosciences, up from $4.7 million in the prior quarter.
  • The five-year high for Operating Leases was $8.0 million in Q4 2024, with the low at $1.8 million in Q3 2024.
  • Average Operating Leases over 3 years is $5.4 million, with a median of $5.9 million recorded in 2025.
  • Peak annual rise in Operating Leases hit 158.37% in 2025, while the deepest fall reached 19.82% in 2025.
  • Over 3 years, Operating Leases stood at $3.2 million in 2023, then soared by 153.64% to $8.0 million in 2024, then fell by 19.82% to $6.5 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $6.5 million, $4.7 million, and $7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.